Cheech Marin and Tommy Chong are making an appearance at El Paso Comic Con 2026, which takes place from May 1-3 at the El Paso convention center.

When I spoke with Cheech & Chong’s team in 2025, the tone leaned more toward business planning than cultural throwback, which makes sense at this stage of the industry. But there’s still room for a ...

As Cheech & Chong, the duo were pioneers of the genre in the '70s Cheech Marin and Tommy Chong are proud of the state of stoner comedy. PEOPLE asked the comedic duo, who pioneered the genre as Cheech ...

Rare disease drug developer BioMarin Pharmaceutical is buying its way to revenue growth with a $4.8 billion deal for Amicus Therapeutics, a company whose two commercialized products each offer ...

Sixteen months after luring former Roche dealmaker James Sabry, M.D., Ph.D., out of retirement and signaling a shift in its business development approach, BioMarin has announced the largest ...

Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN.O), opens new tab said on Friday it would acquire Amicus Therapeutics (FOLD.O), opens new tab for about $4.8 billion, in the drugmaker's second deal ...

Fintel reports that on December 22, 2025, HC Wainwright & Co. maintained coverage of BioMarin Pharmaceutical (NasdaqGS:BMRN) with a Neutral recommendation. Analyst Price Forecast Suggests 50.58% ...

Investing.com - Truist Securities raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $100.00 from $80.00 on Monday, while maintaining a Buy rating on the stock. The new target ...

We recently published 10 Firms in the Limelight. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best performers on Friday. BioMarin Pharmaceutical extended its winning streak to a third ...

Thank you for standing by. My name is Jayel, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioMarin business update. [Operator Instructions] I ...

Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per share in an all-cash transaction, ...